Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase

US12233051B2 · kind B2 · utility

Assignees

• VANDERBILT UNIVERSITY · US
• THE UAB RESEARCH FOUNDATION · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Matthew Hall · Deakins Range, US
• Daniel Jason Urban · Rockville, US
• John Knight · Birmingham, US
• Ross Philip Holmes · Birmingham, US
• Kyle David Wood · Birmingham, US
• Alex G. Waterson · Durham, US
• Victor Darley-Usmar · Birmingham, US
• Leonard M. Neckers · Bethesda, US

Key dates

• Filing date: Jul 14, 2023
• Grant date: Feb 25, 2025
• Expiry date: Jul 14, 2043

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/506
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.